VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total up to $25 million for advancing VedaBio’s CRISPR-based product platform. Moreover, it is an important step in validating VedaBio’s vision of leveraging an amplification-free technology to meet critical unmet needs in decentralized molecular diagnostics.
“The combination of our investors’ support and the strategic agreement with Siemens Healthineers marks a pivotal moment for VedaBio,” said Frederic Sweeney, PhD, President and CEO of VedaBio. “We have assembled one of the most experienced and capable teams in molecular diagnostics which, together with our innovative platform, positions us to redefine how clinical diagnostics are delivered. This milestone not only strengthens our financial position but also aligns us with a world-class leader in the space.”
VedaBio’s amplification-free CRISPR-based approach provides an innovative solution to address significant gaps in patient care.
This announcement follows VedaBio’s recently disclosed partnership with Mammoth Biosciences, which expanded the company’s access to key CRISPR technologies. Together, these milestones underscore VedaBio’s momentum in building a next-generation molecular diagnostics platform as the company continues to advance its product development.
